07:19 AM EDT, 08/27/2026 (MT Newswires) -- AlphaValue/Baader Europe upgraded its rating on Novonesis (NSIS-B.CO), noting that the biosolutions company's risk/reward remains "compelling" after it lifted its 2026 outlook following stronger-than-expected second-quarter results. The research firm changed its opinion to add from reduce on Wednesday, with a price target of 511 Danish kroner. "The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) across both divisions, FY26 guidance raised on genuine demand strength rather than one-off effects, and an inaugural EUR1bn share buyback (H2 26-end-2029), signalling confidence in cash generation and the balance sheet," analysts wrote. "We have improved our medium- to long-term assumptions, and move to ADD."

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.